Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy (original) (raw)

Background HIV-infection is known to aggravate the course of many infectious diseases, including COVID-19. International guidance recommends vaccination of HIV+ individuals against SARS-CoV-2. There is a paucity of data on epidemiological efficacy assessment of COVID-19 vaccines among HIV+. This paper provides a preliminary assessment of Sputnik V vaccine effectiveness in HIV+ patients on antiretroviral therapy (ART). Methods We performed a retrospective cohort study to assess the effectiveness of the standard Sputnik V vaccination regimen in 24,423 HIV+ Moscow residents during spring-summer 2021, that included dominance of delta variant, with estimation of hospitalization and severe illness rates in vaccinated and unvaccinated patients. Data were extracted from the Moscow anti-COVID-19 vaccination and COVID-19 incidence Registries. Findings The data obtained indicate that Sputnik V epidemiological efficiency in the entire cohort of HIV+ on ART was 76¢33%; in HIV+ with CD4+ ≥ 350 cells/µl, vaccine efficiency was 79¢42%, avoiding hospitalization in 90¢12% cases and protecting from the development of moderate or severe disease in 97¢06%. For delta variant in this group the efficiency was 65¢35%, avoiding the need for hospitalization in 75¢77% cases and protecting from the development of moderate or severe disease in 93¢05% of patients. There was a trend, although not statistically significant, of declining vaccine efficiency in immune-compromised individuals (CD4+ < 350 cells/µl). Interpretation The study suggested epidemiological efficiency of immunization with Sputnik V in HIV+ ARTtreated patients for the original and delta SARS-CoV-2 variants.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact